- Conditions
- Bleeding
- Interventions
- Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
- Biological · Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cypress, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–28
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Embolism, Thrombotic Disease
- Interventions
- DS-1040b, Placebo, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
- Conditions
- Embolism, Thrombosis
- Interventions
- Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Deep Venous Thrombosis
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more